More

• Final Glance: Biotechnology companies Wednesday, 19 Jun 2013 | 6:05 PM ET

  Amgen Inc. fell $2.32 or 2.3 percent, to $99.18. Biogen Idec fell $7.00 or 3.3 percent, to $203.80. Celgene Corp. fell $3.35 or 2.8 percent, to $116.89.

• Midday Glance: Biotechnology companies Wednesday, 19 Jun 2013 | 1:19 PM ET

  Amgen Inc. fell$. 65 or. 6 percent, to $100.85. Biogen Idec fell $3.70 or 1.8 percent, to $207.10. Celgene Corp. fell $1.57 or 1.3 percent, to $118.67.

• Early Glance: Biotechnology companies Wednesday, 19 Jun 2013 | 10:32 AM ET

  Amgen Inc. rose$. 04 or percent, to $101.54. Biogen Idec fell$. 98 or. 5 percent, to $209.82. Celgene Corp. fell$. 84 or. 7 percent, to $119.40.

• Final Glance: Biotechnology companies Tuesday, 18 Jun 2013 | 6:01 PM ET

  Amgen Inc. rose $2.42 or 2.4 percent, to $101.50. Biogen Idec rose $3.05 or 1.5 percent, to $210.80. Celgene Corp. rose $2.54 or 2.2 percent, to $120.24.

• Midday Glance: Biotechnology companies Tuesday, 18 Jun 2013 | 1:17 PM ET

  Amgen Inc. rose $2.04 or 2.1 percent, to $101.12. Biogen Idec rose $2.66 or 1.3 percent, to $210.41. Celgene Corp. rose $2.28 or 1.9 percent, to $119.98.

• Early Glance: Biotechnology companies Tuesday, 18 Jun 2013 | 10:21 AM ET

  Amgen Inc. rose$. 74 or. 7 percent, to $99.82. Biogen Idec rose$. 68 or. 3 percent, to $208.43. Celgene Corp. rose$. 37 or. 3 percent, to $118.07.

• Final Glance: Biotechnology companies Monday, 17 Jun 2013 | 6:04 PM ET

  Amgen Inc. rose $1.66 or 1.7 percent, to $99.08. Biogen Idec fell $4.24 or 2.0 percent, to $207.75. Celgene Corp. fell $1.66 or 1.4 percent, to $117.70.

• Midday Glance: Biotechnology companies Monday, 17 Jun 2013 | 1:30 PM ET

  Amgen Inc. rose $2.16 or 2.2 percent, to $99.58. Biogen Idec fell $2.31 or 1.1 percent, to $209.68. Celgene Corp. fell$. 97 or. 8 percent, to $118.40.

• Early Glance: Biotechnology companies Monday, 17 Jun 2013 | 10:29 AM ET

  Amgen Inc. rose $2.14 or 2.2 percent, to $99.56. Biogen Idec rose $1.78 or. 8 percent, to $213.77. Celgene Corp. rose$. 58 or. 5 percent, to $119.94.

• Final Glance: Biotechnology companies Friday, 14 Jun 2013 | 6:02 PM ET

  Amgen Inc. fell $1.09 or 1.1 percent, to $97.42. Biogen Idec rose $2.41 or 1.1 percent, to $211.99. Celgene Corp. fell$. 90 or. 7 percent, to $119.36.

• Midday Glance: Biotechnology companies Friday, 14 Jun 2013 | 1:28 PM ET

  Amgen Inc. fell $1.05 or 1.1 percent, to $97.46. Biogen Idec rose $2.35 or 1.1 percent, to $211.93. Celgene Corp. fell$. 73 or. 6 percent, to $119.53.

• Early Glance: Biotechnology companies Friday, 14 Jun 2013 | 10:37 AM ET

  Amgen Inc. fell$. 67 or. 7 percent, to $97.84. Biogen Idec rose$. 74 or. 4 percent, to $210.32. Celgene Corp. fell$. 71 or. 6 percent, to $119.55.

• FDA backs new for Amgen drug for rare bone tumors Thursday, 13 Jun 2013 | 7:08 PM ET

  Biotech drugmaker Amgen Inc. said Thursday that the Food and Drug Administration has approved a new use for its bone drug Xgeva. The company, based in Thousand Oaks, Calif., said it now can market Xgeva for treating a rare condition, giant cell tumor of bone, when surgery isn't practical.

• Final Glance: Biotechnology companies Thursday, 13 Jun 2013 | 6:04 PM ET

  Amgen Inc. rose $2.14 or 2.2 percent, to $98.51. Biogen Idec rose $3.03 or 1.5 percent, to $209.58. Celgene Corp. rose $2.15 or 1.8 percent, to $120.26.

• Midday Glance: Biotechnology companies Thursday, 13 Jun 2013 | 1:23 PM ET

  Amgen Inc. rose $1.41 or 1.5 percent, to $97.78. Biogen Idec rose $3.06 or 1.5 percent, to $209.61. Celgene Corp. rose $1.88 or 1.6 percent, to $119.99.

• Early Glance: Biotechnology companies Thursday, 13 Jun 2013 | 10:21 AM ET

  Amgen Inc. rose$. 50 or. 5 percent, to $96.87. Biogen Idec rose $1.23 or. 6 percent, to $207.78. Celgene Corp. rose$. 38 or. 3 percent, to $118.49.

• Final Glance: Biotechnology companies Wednesday, 12 Jun 2013 | 6:08 PM ET

  Amgen Inc. fell $1.56 or 1.6 percent, to $96.37. Biogen Idec fell $16.48 or 7.4 percent, to $206.55. Celgene Corp. fell$. 64 or. 5 percent, to $118.11.

• Midday Glance: Biotechnology companies Wednesday, 12 Jun 2013 | 1:17 PM ET

  Amgen Inc. fell $1.27 or 1.3 percent, to $96.66. Biogen Idec fell $15.68 or 7.0 percent, to $207.35. Celgene Corp. rose$. 57 or. 5 percent, to $119.32.

• Amgen says ovarian cancer drug met study goal Wednesday, 12 Jun 2013 | 12:46 PM ET

  THOUSAND OAKS, Calif.-- Biotech drugmaker Amgen Inc. reported Wednesday that its experimental drug for ovarian cancer helped patients live 1.8 months longer without their disease spreading, compared with patients getting placebo. Amgen is studying its drug trebananib in combination with paclitaxel to treat recurring ovarian cancer.

• Cytokinetics and Amgen expand collaboration Wednesday, 12 Jun 2013 | 11:30 AM ET

  NEW YORK-- Cytokinetics Inc. and Amgen Inc. said Wednesday that they are expanding their collaboration on a drug to treat heart failure in a deal worth at least $25 million. Cytokinetics said Amgen will make an upfront payment of $15 million and has agreed to buy $10 million in Cytokinetics stock, or 8.4 million shares for $1.19 per share.